CTLA4 and neoplasm: molecules like programmed cell death protein 1 receptor/ ligand (PD-1, PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) has yielded encouraging outcomes [5–7], emphasizing the essential role of the tumor microenvironment (TME) to influence the clinical therapeutic outcome.